Table 1 The inhibitors for mTORC1/2 complexes that are being tested alone or in combination with other therapeutics in different phases of clinical trials for several known malignancies

AZD2014

N/A

Glioblastoma Multiforme

Phase 1

NCT02619864

AZD2014

Anastrozole

Hormone Receptor-Positive endometrial carcinoma

Phase 1 & 2

NCT02730923

AZD2014

Olaparib and AZD5363

Breast Cancer

Malignant Female Reproductive System Neoplasm

Phase 1 & 2

NCT02208375

Everolimus (RAD001)

N/A

Prostate Cancer Patients with Detectable PSA Following Prostatectomy

Phase 1

NCT01548807

AZD2014

N/A

NF2 Patients with Progressive or Symptomatic Meningiomas

Phase 2

NCT02831257

Vistusertib (AZD2014)

N/A

Recurrent Grade II-III Meningiomas

Phase 2

NCT03071874

Everolimus

Levonorgestrel-Releasing Intrauterine System

Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Phase 2

NCT02397083

AZD2014

Rituximab

Relapsed/Refractory Diffuse Large B Cell Lymphoma

Phase 2

NCT02752204

MLN0128

MLN1117 oral inhibitor of the PI3K (alpha) isoform

Advanced Nonhematologic Malignancies

Phase 1

NCT01899053

Milled MLN0128

API

Unmilled MLN0128 API and Paclitaxel

Advanced Nonhematologic Malignancies

Phase 1

NCT02412722

MLN2480

MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan

Advanced Nonhematologic Malignancies

Phase 1B

NCT02327169

AZD2014

Paclitaxel

Ovarian cancer

Squamous cell lung cancer

Phase 1

NCT02193633

TAK228

Paclitaxel

advanced/Recurrent Epithelial Ovarian, Fallopian Tube

Primary Peritoneal Cancer

Phase 2

NCT03648489

Sirolimus

N/A

Cardiovascular Abnormalities/Vascular Malformations

Phase 3

NCT01811667

AP23573 (Ridaforolimu)

N/A

Advanced Sarcoma

Phase 2

NCT00093080

Rapamycin

Placebo

Aging and associated complications

Phase 2

NCT02874924

Everolimus

Imatinib mesylate

Metastatic or Unresectable Kidney Cancer

Phase 2

NCT00331409

MLN0128

Paclitaxel; Trastuzumab

Advanced Solid Malignancies Hematologic Malignancies

Phase 1

NCT01351350

WXFL10030390

N/A

Advanced Solid Tumors

Lymphoma

Phase 1

NCT03730142

Metformin

N/A

Well-differentiated Neuroendocrine Tumors

Phase 2

NCT02279758

SF1126

N/A

Advanced or Metastatic Solid Tumors

Phase 1

NCT00907205

Everolimus

N/A

Chronic Allograft Dysfunction in Renal Transplantation

Phase 4

NCT01046045

Sirolimus

N/A

Congenital Vascular Malformations

Phase 3

NCT03987152

Sirolimus

N/A

Peutz-Jeghers Syndrome

Phase 4

NCT03781050

RAD001 (Everolimus)

N/A

Tuberous Sclerosis Lymphangioleiomyomatosis

Phase 1 & 2

NCT00457964

RAD001 (Everolimus)

N/A

Subependymal Giant Cell Astrocytoma

Tuberous Sclerosis

Phase 1 & 2

NCT00411619

RAD001 (Everolimus)

N/A

Epilepsy

Tuberous Sclerosis Complex

Phase 1 & 2

NCT01070316

Sirolimus

Placebo

Polycystic Kidney,

Type 1 & Type 2 Autosomal Dominant Disease

Phase 3

NCT02055079

Sirolimus

N/A

Blue Rubber Bleb Nevus Syndrome Hereditary

Sporadic Venous Malformation

Phase 4

NCT03767660

Gedatolisib

Palbociclib/Letrozole Or Palbociclib/Fulvestrant

Metastatic Breast Cancer

Phase 1B

NCT02684032

Arm 1 Everolimus/

tacrolimus

Calcineurin inhibitors

Renal Transplant and associated complications

Phase 4

NCT01935128; [80]

RAD001 (Everolimus)

Placebo

Tuberous Sclerosis Complex (TSC) Lymphangioleiomyomatosis (LAM)

Phase 3

NCT00790400; [80]

CCI-779 (Temsirolimus)

N/A

Breast and Renal cancer

Phase 2

[73]